Could HTAs manage uncertainty more effectively?

Uncertainty in economic evaluation of innovative therapies is often managed by a call for more evidence.  However, the willingness to invest in research to obtain additional evidence may be limited by the number of patients, the heterogeneity and natural history of the disease, the mechanism of action of the therapy, and the ethical issues surrounding a specific patient population.  If the region of uncertainty is wide, but if the treatment has significant potential benefits, interim of conditional funding should be considered, provided that data are collected during further use of the therapy in order to improve an informed decision.